MAb therapy against the IFN-α/β receptor subunit 1 stimulates arteriogenesis in a murine hindlimb ischaemia model without enhancing atherosclerotic burden

Cardiovascular Research

Volumn 107, Issue 2, 2015, Pages 255-266

  Teunissen, Paul F A ^a   Boshuizen, Marieke C ^b   Hollander, Maurits R ^a   Biesbroek, Paul S ^a   Van Der Hoeven, Nina W ^a   Mol, Jan Quinten ^a   Gijbels, Marion J ^b,c   Van Der Velden, Saskia ^b   Van Der Pouw Kraan, Tineke C ^a   Horrevoets, Anton J ^a   De Winther, Menno P ^b   Van Royen, Niels ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Animal model cardiovascular disease; Atherosclerosis; Collateral circulation; Cytokine; MAbs

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA BETA INTERFERON RECEPTOR SUBUNIT 1; APOLIPOPROTEIN E; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; MAR 1 5A 3MAB; MONOCLONAL ANTIBODY; RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EFFECT; EXPERIMENTAL ATHEROSCLEROSIS; FEMALE; FEMORAL ARTERY; HINDLIMB; IMMUNOHISTOCHEMISTRY; LIMB ISCHEMIA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCINTIGRAPHY; ANIMAL; ATHEROSCLEROSIS; COLLATERAL CIRCULATION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; ISCHEMIA; KNOCKOUT MOUSE; METABOLISM; MONOCYTE; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; COLLATERAL CIRCULATION; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; HINDLIMB; ISCHEMIA; MACROPHAGES; MICE, KNOCKOUT; MONOCYTES; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 84938898707     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv138     Document Type: Article

References (46)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
2. Fung E, Helisch A. Macrophages in collateral arteriogenesis. Front Physiol 2012;3:353.
3. Cai W, Schaper W. Mechanisms of arteriogenesis. Acta Biochim Biophys Sin (Shanghai) 2008;40:681-692.
4. Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C. The impact of the coronary collateral circulation on mortality: a meta-analysis. Eur Heart J 2012;33:614-621.
5. Gloekler S, Traupe T, Stoller M, Schild D, Steck H, Khattab A, Vogel R, Seiler C. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart 2014;100:160-166.
6. Schirmer SH, Fledderus JO, Bot PT, Moerland PD, Hoefer IE, Baan J Jr, Henriques JP, van der Schaaf RJ, Vis MM, Horrevoets AJ, Piek JJ, van Royen N. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res 2008;102:1286-1294.
7. Schirmer SH, Bot PT, Fledderus JO, van der Laan AM, Volger OL, Laufs U, Bohm M, de Vries CJ, Horrevoets AJ, Piek JJ, Hoefer IE, van Royen N. Blocking interferon {beta} stimulates vascular smooth muscle cell proliferation and arteriogenesis. J Biol Chem 2010;285:34677-34685.
8. van Royen N, Hoefer I, Buschmann I, Kostin S, Voskuil M, Bode C, Schaper W, Piek JJ. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. Cardiovasc Res 2003;57:178-185.
9. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, van der Made I, Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Kalinke U, Weber C, Lutgens E, de Winther MP. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 2010;12:142-153.
10. van Royen N, Hoefer I, Bottinger M, Hua J, Grundmann S, Voskuil M, Bode C, Schaper W, Buschmann I, Piek JJ. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 2003;92:218-225.
11. Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ, Schreiber RD. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) frommice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 2006;26:804-819.
12. van der Laan AM, Schirmer SH, de Vries MR, Koning JJ, Volger OL, Fledderus JO, Bastiaansen AJ, Hollander MR, Baggen JM, Koch KT, Baan J Jr, Henriques JP, van der Schaaf RJ, Vis MM, Mebius RE, van der Pouw Kraan TC, Quax PH, Piek JJ, Horrevoets AJ, van Royen N. Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. Eur Heart J 2012;33:1076-1084.
13. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol 1998;152:1667-1679.
14. Scholz D, Ziegelhoeffer T, Helisch A, Wagner S, Friedrich C, Podzuweit T, Schaper W. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 2002;34:775-787.
15. Poole KM, Tucker-Schwartz JM, Sit WW, Walsh AJ, Duvall CL, Skala MC. Quantitative optical imaging of vascular response in vivo in a model of peripheral arterial disease. Am J Physiol Heart Circ Physiol 2013;305:H1168-H1180.
16. Ke LD, Fueyo J, Chen X, Steck PA, Shi YX, Im SA, Yung WK. A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 1998;12:1391-1396.
17. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841-850.
18. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013;228:18-28.
19. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605.
20. Hellingman AA, van der Vlugt LE, Lijkwan MA, Bastiaansen AJ, Sparwasser T, Smits HH, Hamming JF, Quax PH. A limited role for regulatory T cells in post-ischemic neovascularization. J Cell Mol Med 2012;16:328-336.
21. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, Hamilton JA, Whitty G, Bertoncello I, Kola I. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci USA 1995;92:11284-11288.
22. Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, Sheehan KC, Murphy KM, Schreiber RD, Diamond MS. A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS Pathog 2011;7:e1002407.
23. van den Borne P, Haverslag RT, Brandt M, Cheng C, Duckers HJ, Quax PHA, Hoefer IE, Pasterkamp G, de Kleijn DPV. Absence of chemokine (C-X-C motif) ligand 10 diminishes perfusion recovery after local arterial occlusion in mice. Arterioscler Thromb Vasc Biol 2014;34:594-602.
24. Campanella GS, Colvin RA, Luster AD. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One 2010;5:e12700.
25. Luster AD, Cardiff RD, MacLean JA, Crowe K, Granstein RD. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc Assoc Am Physicians 1998;110:183-196.
26. Glaser J, Gonzalez R, Perreau VM, Cotman CW, Keirstead HS. Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury. J Neurosci Res 2004;77:701-708.
27. Bodnar RJ, Yates CC, Rodgers ME, Du X, Wells A. IP-10 induces dissociation of newly formed blood vessels. J Cell Sci 2009;122(Pt 12):2064-2077.
28. Troidl C, Jung G, Troidl K, Hoffmann J, Mollmann H, Nef H, Schaper W, Hamm CW, Schmitz-Rixen T. The temporal and spatial distribution of macrophage subpopulations during arteriogenesis. Curr Vasc Pharmacol 2013;11:5-12.
29. Wu S, Wu X, Zhu W, Cai WJ, Schaper J, Schaper W. Immunohistochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogenesis. Mol Cell Biochem 2010;343:223-229.
30. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med 2003;13:169-175.
31. Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A, Rabquer BJ, Koch AE, Pennathur S, Davidson A, Eitzman DT, Kaplan MJ. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012;64:2975-2985.
32. Stabile E, Burnett MS, Watkins C, Kinnaird T, Bachis A, la Sala A, Miller JM, Shou M, Epstein SE, Fuchs S. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation 2003;108:205-210.
33. Sharir R, Semo J, Shaish A, Landa-Rouben N, Entin-Meer M, Keren G, George J. Regulatory T cells influence blood flow recovery in experimental hindlimb ischaemia in an IL-10-dependent manner. Cardiovasc Res 2014;103:585-596.
34. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 1997;80:829-837.
35. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev 2007;6:975-990.
36. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2013;207:2053-2063.
37. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type 1 interferons. Curr Opin Immunol 2006;18:676-682.
38. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007;110:2907-2915.
39. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-a. Circulation 2006;114:2482-2489.
40. Döring Y, Manthey HD, Drechsler M, Lievens D, Megens RT, Soehnlein O, Busch M, Manca M, Koenen RR, Pelisek J, Daemen MJ, Lutgens E, Zenke M, Binder CJ, Weber CJ, Zernecke A. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012;125:1673-1683.
41. Sage AP, Murphy D, Maffia P, Masters LM, Sabir SR, Baker LL, Cambrook H, Finigan AJ, Ait-Oufella H, Grassia G, Harrison JE, Ludewig B, Reith W, Hansson GK, Reizis B, Hugues S, Mallat Z. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation 2014;130:1363-1373.
42. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994;93:1885-1893.
43. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010;10:36-46.
44. Van Weyenbergh J, Wietzerbin J, Rouillard D, Barral-Netto M, Liblau R. Treatment of multiple sclerosis patients with interferon-β primes monocyte-derived macrophages for apoptotic cell death. J Leukoc Biol 2001;70:745-748.
45. Graber J, Zhan M, Ford D, Kursch F, Francis G, Bever C, Panitch H, Calabresi PA, Dhib-Jalbut S. Interferon-β-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol 2005;161:169-176.
46. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AL, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell R, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006;2:178-180.